(Total Views: 494)
Posted On: 11/24/2020 1:53:04 AM
Post# of 36569
https://www.bioworld.com/articles/500484-othe...ov-23-2020
Biotechnology Corp., of Miramar, Fla., and subsidiary Nugenerex Immuno-Oncology said their COVID-19 vaccine development partner, Bintai Kinden Corp., of Malaysia, and its subsidiary, Bintai Healthcare, executed their exclusive option to license and distribute the vaccine in Australia and New Zealand if approved by the FDA and Malaysian authorities. Nugenerex is developing immunotherapeutic peptide vaccines for cancer and infectious disease based on its CD4 T-cell activation platform.
Biotechnology Corp., of Miramar, Fla., and subsidiary Nugenerex Immuno-Oncology said their COVID-19 vaccine development partner, Bintai Kinden Corp., of Malaysia, and its subsidiary, Bintai Healthcare, executed their exclusive option to license and distribute the vaccine in Australia and New Zealand if approved by the FDA and Malaysian authorities. Nugenerex is developing immunotherapeutic peptide vaccines for cancer and infectious disease based on its CD4 T-cell activation platform.
(1)
(0)
